Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors

Por Cortes, J., Digumarti, R., Parikh, P.M., Wetzler, M., Lipton, J.H., Hochhaus, A., Craig, A.R., Benichou, A.-C., Nicolini, F.E., Kantarjian, H.M.
Publicado no Am J Hematol (2013)